Express Scripts Holding Co (ESRX)

ESRX (NASDAQ:Health Services) EQUITY
$61.04
neg -0.96
-1.55%
Today's Range: 60.92 - 62.24 | ESRX Avg Daily Volume: 3,509,000
Last Update: 08/17/17 - 4:00 PM EDT
Volume: 2,854,250
YTD Performance: -9.87%
Open: $61.86
Previous Close: $62.00
52 Week Range: $65.55 - $94.22
Oustanding Shares: 577,549,000
Market Cap: 35,652,099,770
6-Month Chart
TheStreet Ratings Grade for ESRX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 6
Moderate Buy 0 0 0 0
Hold 9 8 8 9
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.49 2.46 2.46 2.49
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 10.81
Price Earnings Comparisons:
ESRX Sector Avg. S&P 500
10.81 10.80 36.10
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
3.06% -19.45% -15.12%
GROWTH 12 Mo 3 Yr CAGR
Revenue -1.40 0.00 -0.01
Net Income 37.10 0.80 0.21
EPS 51.40 1.40 0.33
Earnings for ESRX:
EBITDA 7.24B
Revenue 100.29B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $1.90 $2.05 $7.00 $7.65
Number of Analysts 12 10 13 13
High Estimate $1.91 $2.07 $7.04 $7.80
Low Estimate $1.88 $2.01 $6.95 $7.55
Prior Year $1.74 $1.88 $6.39 $7.00
Growth Rate (Year over Year) 9.24% 8.78% 9.51% 9.38%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Update
Jul 21, 2017 | 8:39 AM EDT
Needham initiated stock coverage of Express Scripts with a "Hold" rating.
I was pleasantly surprised to see that the candies are still crushing it.

When to Ignore the Bad News Real Money Pro($)

Fallout from dispute with Anthem, its largest customer, presents an opportunity.
Bearish
Apr 26, 2017 | 9:02 AM EDT
Edward Jones downgraded Express Scripts to "Hold" from "Buy."
* Biotech (Allergan (AGN) , Celgene (CELG) and Gilead Sciences (GILD) ) * Speculative biotech ( ZIOPHARM Oncology (ZIOP) ,   SAGE Therapeutics (SAGE) , Intrexon (XON) , Valeant Pharmaceuticals (VRX) ,   ACADIA Pharmaceuticals (ACAD) , FibroGen  (FGEN) ). * DuPont (DD) , Netflix (NFLX) , Baidu (BIDU) , Radian (RDN) and Biogen   (BIIB) . * New tech - (T)FANG (TSLA) , (FB) , (AAPL) , (NFLX) , (GOOGL) . * Chipotle Mexican Grill (
Its earnings are more than double what they were five years ago, but the stock price is the same.
Bearish
Mar 15, 2017 | 6:49 AM EDT
ESRX was downgraded from Market Perform to Underperform, Wells Fargo said. Loss of the Anthem contract could hurt annual earnings by 20...
The stock has taken a beating, but users of Afrezza are loyal to the drug.
Six reasons why the Nasdaq 100 ETF seems ready to pull back.

Columnist Conversations

View Chart »  View in New Window »
View Chart »  View in New Window »

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.